Cannabinoid and Terpenoid Doses are Associated with Adult ADHD Status of Medical Cannabis Patients Jeffrey Y. Hergenrather, Joshua Aviram, Yelena Vysotski, Salvatore Campisi-Pinto, Gil M. Lewitus and David Meiri. Rambam Maimonides Medical Journal, 2020, 11, (1), e0001 Doi : 10.5041/RMMJ.10384 Methods : Participants were adult patients licensed for medical cannabis (MC) treatment who also reported a diagnosis of ADHD by a physician. Data on demographics, ADHD, sleep, and anxiety were collected using self-report questionnaires. Data collected on MC treatment included administration route, cultivator, cultivar name, and monthly dose. Comparison statistics were used to evaluate differences in reported parameters between low (20–30 g, n=18) and [...]
Lire la suiteKetamine Promising in Cocaine Addiction Batya Swift Yasgur, MA, LSW Medscape.com, July 05, 2019 https://www.medscape.com/viewarticle/915260_print A single ketamine infusion combined with mindfulness-based relapse prevention therapy (MBRP) improves abstinence and cuts cravings in cocaine-dependent adults, new research suggests. Results of a randomized control trial show that rates of abstinence were significiantly higher in patients who received ketamine plus MBRP compared to control patients. Moreover, those in the group that received ketamine were significantly less likely to experience relapse compared to control persons, and cravings were also significantly lower in the ketamine group throughout the trial. "In individuals receiving MBRP, a single ketamine infusion led to significantly greater odds [...]
Lire la suiteThe Psychiatric Consequences of Cannabinoids Joao P. De Aquino, Mohamed Sherif, Rajiv Radhakrishnan, John D. Cahill, Mohini Ranganathan and Deepak C. D’Souza Clinical Therapeutics, 2018, 40, (9), 14481456 Doi : 10.1016/j.clinthera.2018.03.013 ABSTRACT With rising rates of cannabis use in the general population and an increasing number of US states legalizing both recreational and medical cannabis use, it is important to be informed about the adverse consequences of cannabinoids. This Commentary provides an overview of the psychiatric effects of plant-based and synthetic cannabinoids, differentiating acute effects from effects associated with persistent use. Cannabinoids produce multiphasic and dose dependent effects on anxiety, mood, and perception, in addition [...]
Lire la suiteIntensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study Joseph Barsuglia, Alan K. Davis, Robert Palmer, Rafael Lancelotta, Austin-Marley Windham-Herman, Kristel Peterson, Martin Polanco, Robert Grant and Roland R. Griffiths Frontiers in Psychology, 2018, Vol 9, Article doi : 10.3389/fpsyg.2018.02459 5-MeO-DMT is a psychoactive substance found in high concentrations in the bufotoxin of the Colorado River Toad (Bufo alvarius). Emerging evidence suggests that vaporized 5-MeO-DMT may occasion mystical experiences of comparable intensity to those occasioned by more widely studied psychedelics such as psilocybin, but no empirical study has tested this hypothesis. Data was obtained from 20 individuals (Mage = [...]
Lire la suiteSpecies-specific susceptibility to cannabis-induced convulsions Benjamin J Whalley, Hong Lin, Lynne Bell, Thomas Hill, Amesha Patel, Roy A Gray, C Elizabeth Roberts, Orrin Devinsky, Michael Bazelot, Claire M Williams and Gary J Stephens British Journal of Pharmacology, 2018, 1-18. Doi : 10.1111/bph.14165 BACKGROUND AND PURPOSE Numerous claims are made for cannabis’ therapeutic utility upon human seizures, but concerns persist about risks. A potential confounder is the presence of both Δ9-tetrahydrocannabinol (THC), variously reported to be pro- and anticonvulsant, and cannabidiol (CBD), widely confirmed as anticonvulsant. Therefore, we investigated effects of prolonged exposure to different THC/CBD cannabis extracts on seizure activity and associated measures of endocannabinoid [...]
Lire la suiteCannabinoids in Pain Management and Palliative Medicine An Overview of Systematic Reviews and Prospective Observational Studies Winfried Häuser, Mary-Ann Fitzcharles, Lukas Radbruch, Frank Petzke The Deutsches Ärzteblatt International, 2017, 114, 627–634. Doi : 10.3238/arztebl.2017.0627 SUMMARY Background : There are conflicting interpretations of the evidence regarding the efficacy, tolerability, and safety of cannabinoids in pain management and palliative medicine. Methods : We conducted a systematic review (SR) of systematic reviews of randomized controlled trials (RCT) and prospective long-term observational studies of the use of cannabinoids in pain management and palliative medicine. Pertinent publications from January 2009 to January 2017 were retrieved by a selective search in the Cochrane [...]
Lire la suiteLe cannabigerol est efficace contre les infections par des bactéries résistantes aux antibiotiques Le cannabigérol (CBG), un cannabinoïde de la plante de cannabis, s’avère pouvoir détruire les bactéries résistantes aux médicaments, suscitant l’espoir d’une nouvelle arme dans la lutte contre les superbactéries. Les scientifiques ont examiné cinq cannabinoïdes pour leurs propriétés antibiotiques et ont découvert que le cannabigérol (CBG) était particulièrement puissant pour tuer le Staphylococcus aureus résistant à la méthicilline (SARM), l’une des super-bactéries les plus courantes dans les hôpitaux. Après avoir vu l’efficacité de la substance contre les bactéries en laboratoire, les chercheurs ont décidé de tester la capacité du [...]
Lire la suiteThe Impact of Medical Cannabis on Intermittent and Chronic Opioid Users with Back Pain : How Cannabis Diminished Prescription Opioid Usage Kevin M. Takakuwa, Jeffrey Y. Hergenrather, Frances S. Shofer, and Raquel M. Schears Cannabis and Cannabinoid Research, 2020, Volume X, Number X, 1-8. Doi : 10.1089/can.2019.0039 Abstract Objective : To determine if cannabis may be used as an alternative or adjunct treatment for intermittent and chronic prescription opioid users. Design : Retrospective cohort study. Setting : A single-center cannabis medical practice site in California. Patients : A total of 180 patients who had a chief complaint of low back pain were identified (International Classification of Diseases, 10th [...]
Lire la suiteIACM-Bulletin du 14 Février 2020 Science/Animal: Le cannabigerol est efficace contre les infections par des bactéries résistantes aux antibiotiques Economy/Écologie: Données sur la quantité d'électricité consommée par l'industrie du cannabis Science/Homme: Environ la moitié des patients souffrant de lombalgie ont pu arrêter toute consommation d'opioïdes après avoir commencé la consommation de cannabis Europe/ONU: La Commission Européenne propose un vote unifié de l'UE sur la programmation de l’OMS sur le cannabis Science/Homme: De nombreux patients atteints d'arthrite consomment du cannabis Science/Homme: Le cannabis peut être utile contre l'insomnie chez les personnes âgées souffrant de douleur [...]
Lire la suiteClinical and Toxicological Profile of NBOMes : A Systematic Review Nino Cesar Marchi, Juliana Nichterwitz Scherer, Letícia Schwanck Fara, Lysa Remy, Rafaela Ornel, Monique Reis, Amanda Zamboni, Mariana Paim, Taís Regina Fiorentin, Carlos Alberto Yasin Wayhs, Lisia Von Diemen, Flavio Pechansky, Felix Henrique Paim Kessler, Renata Pereira Limberger Psychosomatics, 2019 Mar - Apr, 60, (2), 129-138. doi : 10.1016/j.psym.2018.11.002 Background : NBOMes are a new class of potent hallucinogens widely present in illicit drugs. Little is known about this class of drugs, regarding its detection and clinical manifestations of intoxication. Objective : This study aims to enhance care involving NBOMes by reviewing the literature on their [...]
Lire la suite